Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 14

1.

ImmunoPET and near-infrared fluorescence imaging of CD105 expression using a monoclonal antibody dual-labeled with (89)Zr and IRDye 800CW.

Zhang Y, Hong H, Severin GW, Engle JW, Yang Y, Goel S, Nathanson AJ, Liu G, Nickles RJ, Leigh BR, Barnhart TE, Cai W.

Am J Transl Res. 2012;4(3):333-46. Epub 2012 Jul 27.

2.

Multimodality imaging of breast cancer experimental lung metastasis with bioluminescence and a monoclonal antibody dual-labeled with 89Zr and IRDye 800CW.

Hong H, Zhang Y, Severin GW, Yang Y, Engle JW, Niu G, Nickles RJ, Chen X, Leigh BR, Barnhart TE, Cai W.

Mol Pharm. 2012 Aug 6;9(8):2339-49. doi: 10.1021/mp300277f. Epub 2012 Jul 19.

3.

Positron emission tomography imaging of tumor angiogenesis with a 66Ga-labeled monoclonal antibody.

Engle JW, Hong H, Zhang Y, Valdovinos HF, Myklejord DV, Barnhart TE, Theuer CP, Nickles RJ, Cai W.

Mol Pharm. 2012 May 7;9(5):1441-8. doi: 10.1021/mp300019c. Epub 2012 Apr 21.

4.

In vivo targeting and positron emission tomography imaging of tumor vasculature with (66)Ga-labeled nano-graphene.

Hong H, Zhang Y, Engle JW, Nayak TR, Theuer CP, Nickles RJ, Barnhart TE, Cai W.

Biomaterials. 2012 Jun;33(16):4147-56. doi: 10.1016/j.biomaterials.2012.02.031. Epub 2012 Mar 3.

5.

In vivo targeting and imaging of tumor vasculature with radiolabeled, antibody-conjugated nanographene.

Hong H, Yang K, Zhang Y, Engle JW, Feng L, Yang Y, Nayak TR, Goel S, Bean J, Theuer CP, Barnhart TE, Liu Z, Cai W.

ACS Nano. 2012 Mar 27;6(3):2361-70. doi: 10.1021/nn204625e. Epub 2012 Feb 16.

6.

Positron emission tomography and optical imaging of tumor CD105 expression with a dual-labeled monoclonal antibody.

Zhang Y, Hong H, Engle JW, Yang Y, Theuer CP, Barnhart TE, Cai W.

Mol Pharm. 2012 Mar 5;9(3):645-53. doi: 10.1021/mp200592m. Epub 2012 Jan 31.

7.

Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105.

Hong H, Severin GW, Yang Y, Engle JW, Zhang Y, Barnhart TE, Liu G, Leigh BR, Nickles RJ, Cai W.

Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):138-48. doi: 10.1007/s00259-011-1930-x. Epub 2011 Sep 10.

8.

In vivo near-infrared fluorescence imaging of CD105 expression during tumor angiogenesis.

Yang Y, Zhang Y, Hong H, Liu G, Leigh BR, Cai W.

Eur J Nucl Med Mol Imaging. 2011 Nov;38(11):2066-76. doi: 10.1007/s00259-011-1886-x. Epub 2011 Aug 4.

9.

Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy.

Nassiri F, Cusimano MD, Scheithauer BW, Rotondo F, Fazio A, Yousef GM, Syro LV, Kovacs K, Lloyd RV.

Anticancer Res. 2011 Jun;31(6):2283-90. Review.

PMID:
21737653
10.

Positron emission tomography imaging of CD105 expression during tumor angiogenesis.

Hong H, Yang Y, Zhang Y, Engle JW, Barnhart TE, Nickles RJ, Leigh BR, Cai W.

Eur J Nucl Med Mol Imaging. 2011 Jul;38(7):1335-43. doi: 10.1007/s00259-011-1765-5. Epub 2011 Mar 4.

11.

The role of the TGF-β coreceptor endoglin in cancer.

Pérez-Gómez E, Del Castillo G, Juan Francisco S, López-Novoa JM, Bernabéu C, Quintanilla M.

ScientificWorldJournal. 2010 Dec 14;10:2367-84. doi: 10.1100/tsw.2010.230. Review.

12.

Endoglin-targeted cancer therapy.

Seon BK, Haba A, Matsuno F, Takahashi N, Tsujie M, She X, Harada N, Uneda S, Tsujie T, Toi H, Tsai H, Haruta Y.

Curr Drug Deliv. 2011 Jan;8(1):135-43. Review.

13.

Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours.

Fonsatti E, Nicolay HJ, Altomonte M, Covre A, Maio M.

Cardiovasc Res. 2010 Apr 1;86(1):12-9. doi: 10.1093/cvr/cvp332. Epub 2009 Oct 7. Review.

PMID:
19812043
14.

Antiangiogenic chimeric anti-endoglin (CD105) antibody: pharmacokinetics and immunogenicity in nonhuman primates and effects of doxorubicin.

Shiozaki K, Harada N, Greco WR, Haba A, Uneda S, Tsai H, Seon BK.

Cancer Immunol Immunother. 2006 Feb;55(2):140-50. Epub 2005 Apr 23.

PMID:
15856228

Supplemental Content

Support Center